These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 30099714)

  • 1. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
    El-Sherbeny WS; Sabry NM; Sharbay RM
    J Echocardiogr; 2019 Jun; 17(2):76-83. PubMed ID: 30099714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
    Keramida K; Farmakis D; Bingcang J; Sulemane S; Sutherland S; Bingcang RA; Ramachandran K; Tzavara C; Charalampopoulos G; Filippiadis D; Kouris N; Nihoyannopoulos P
    Eur J Heart Fail; 2019 Apr; 21(4):529-535. PubMed ID: 30811091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
    Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
    Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy.
    Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Chow CM; Thavendiranathan D; Haq R; Barfett JJ; Petrella TM; Connelly KA; Yan AT
    Int J Cardiol; 2018 Jun; 261():228-233. PubMed ID: 29555336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
    Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
    Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
    Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
    Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy.
    Cadeddu C; Piras A; Dessì M; Madeddu C; Mantovani G; Scartozzi M; Hagendorff A; Colonna P; Mercuro G
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):197-207. PubMed ID: 27696298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
    Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
    Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
    J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
    Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
    JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global longitudinal strain at 3 months after therapy can predict late cardiotoxicity in breast cancer.
    Liu Z; Liu M; Zhong X; Qin Y; Liang T; Luo T; Yan X; Tang Z; Wang X; Liang S; Li Q; Ruan X; He W; Huang H
    Cancer Med; 2023 Jun; 12(12):13374-13387. PubMed ID: 37183826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of left ventricular global longitudinal strain on speckle echocardiography for predicting chemotherapy-induced cardiotoxicity in breast cancer patients: A systematic review and meta-analysis.
    Li L; Jiang X; Xie Q
    Echocardiography; 2023 Apr; 40(4):306-317. PubMed ID: 36859694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
    Bergamini C; Niro L; Springhetti P; Ferri L; Trento L; Minnucci I; Maffeis C; Tafciu E; Rossi A; Fiorio E; Benfari G; Ribichini F
    Cardiovasc Toxicol; 2024 Jun; 24(6):550-562. PubMed ID: 38696070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speckle tracking echocardiography predicts early subclinical anthracycline cardiotoxicity in patients with breast cancer.
    Tang Q; Jiang Y; Xu Y; Xia H
    J Clin Ultrasound; 2017 May; 45(4):222-230. PubMed ID: 27910996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
    Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity.
    Negishi K; Negishi T; Hare JL; Haluska BA; Plana JC; Marwick TH
    J Am Soc Echocardiogr; 2013 May; 26(5):493-8. PubMed ID: 23562088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.